Ivermectin administration is associated with lower gastrointestinal complications and greater ventilator-free days in ventilated patients with COVID-19: A propensity score analysis

Shimizu et al., Journal of Infection and Chemotherapy, doi:10.1016/j.jiac.2021.12.024

Dec 2021

Source PDF All Studies Meta AnalysisMeta

Retrospective 88 ventilated COVID-19 patients in Japan, 39 treated with ivermectin within 3 days of admission, showing significantly reduced incidence of GI complications and mortality, and increased ventilator-free days with treatment.

This is the 74th of 99 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 2 sextillion). 46 studies are RCTs, which show efficacy with p=0.00000014.

Important missing comments or errors? Let us know.

risk of death, 99.9% lower, HR 0.001, p < 0.001, treatment 0 of 39 (0.0%), control 8 of 49 (16.3%), NNT 6.1, adjusted per study, Cox proportional hazard regression.

ventilator free days, 47.9% lower, OR 0.52, p = 0.03, treatment 39, control 49, adjusted per study, inverted to make OR<1 favor treatment, proportional odds logistic regression, primary outcome, RR approximated with OR.

ventilation time, 38.5% lower, relative time 0.62, p < 0.001, treatment 39, control 49.

ICU free days, 42.8% lower, OR 0.57, p = 0.06, treatment 39, control 49, adjusted per study, inverted to make OR<1 favor treatment, proportional odds logistic regression, RR approximated with OR.

ICU time, 37.5% lower, relative time 0.62, p < 0.001, treatment 39, control 49.

GI complications while ventilated, 77.9% lower, RR 0.22, p = 0.03, treatment 39, control 49, adjusted per study, Cox proportional hazard regression.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Shimizu et al., 31 Dec 2021, retrospective, Japan, peer-reviewed, 11 authors, study period December 2020 - May 2021, dosage 200μg/kg days 1, 14.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Ivermectin All

Ivermectin administration is associated with lower gastrointestinal complications and greater ventilator-free days in ventilated patients with COVID-19: A propensity score analysis

M.D. Kentaro Shimizu, Haruhiko Hirata, Daijiro Kabata, Natsuko Tokuhira, Moe Koide, Akiko Ueda, Jotaro Tachino, Ayumi Shintani, Akinori Uchiyama, Yuji Fujino, Hiroshi Ogura

Journal of Infection and Chemotherapy, doi:10.1016/j.jiac.2021.12.024

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conclusions The administration of ivermectin improved GI complications and VFD in ventilated patients with COVID-19. The beneficial influence of ivermectin on the intestines may improve outcome in these patients. Further research is needed to investigate the mechanism and effects of ivermectin treatment. Conflict of interest The authors declare that they have no conflict of interests.

References

Beigel, What is the role of remdesivir in patients with covid-19?, Curr Opin Crit Care, doi:10.1097/MCC.0000000000000866

Bone, Balk, Cerra, Dellinger, Fein et al., Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The accp/sccm consensus conference committee. American college of chest physicians/society of critical care medicine, Chest

Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of sars-cov-2 in vitro, Antiviral Res

Clark, Coopersmith, Intestinal crosstalk: A new paradigm for understanding the gut as the "motor" of critical illness, Shock

D'amico, Baumgart, Danese, Peyrin-Biroulet, Diarrhea during covid-19 infection: Pathogenesis, epidemiology, prevention, and management, Clin Gastroenterol Hepatol

Group, Horby, Lim, Emberson, Mafham et al., Dexamethasone in hospitalized patients with covid-19, N Engl J Med

Hashimoto, Perlot, Rehman, Trichereau, Ishiguro et al., Ace2 links amino acid malnutrition to microbial ecology and intestinal inflammation, Nature

Lopez-Medina, Lopez, Hurtado, Davalos, Ramirez et al., Effect of ivermectin on time to resolution of symptoms among adults with mild covid-19: A randomized clinical trial, JAMA

Lv, Gu, Jiang, Yan, Chen et al., Gut mycobiota alterations in patients with covid-19 and h1n1 infections and their associations with clinical features, Commun Biol

Mao, Qiu, He, Tan, Li et al., Manifestations and prognosis of gastrointestinal and liver involvement in patients with covid-19: A systematic review and meta-analysis, Lancet Gastroenterol Hepatol

Mikasa, Aoki, Aoki, Abe, Iwata et al., JAID/JSC guidelines for the treatment of respiratory infectious diseases: The japanese association for infectious diseases/japanese society of chemotherapy -the JAID/JSC guide to clinical management of infectious disease/guideline-preparing committee respiratory infectious disease wg. J Infect J o u r n a l P r e -p r o, o f Chemother

Rajter, Sherman, Fatteh, Vogel, Sacks et al., Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: The ivermectin in covid nineteen study, Chest

Salem, A response to the recommendations for using dexamethasone for the treatment of covid-19: The dark side of dexamethasone, J Pharm Pract

Schmith, Zhou, Lohmer, The approved dose of ivermectin alone is not the ideal dose for the treatment of covid-19, Clin Pharmacol Ther

Schoenfeld, Bernard, Network, Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome, Crit Care Med

Shimizu, Hibino, Biros, Irisawa, Shimazu, Emergency medicine in japan: Past, present, and future, International Journal of Emergency Medicine

Wang, Zhang, Du, Du, Zhao et al., Remdesivir in adults with severe covid-19: A J o u r n a l P r e -p r o o f randomised, double-blind, placebo-controlled, multicentre trial, Lancet

Wehbe, Wehbe, Iratni, Pintus, Zaraket et al., Repurposing ivermectin for covid-19: Molecular aspects and therapeutic possibilities, Front Immunol

White, Dhillon, Hughes, Faggian, Soni, A national strategy to diagnose covid-19 associated invasive fungal disease in the icu, Clin Infect Dis, doi:10.1093/cid/ciaa1298

Wu, Cheng, Jiang, Tang, Tang, Altered oral and gut microbiota and its association with sars-cov-2 viral load in covid-19 patients during hospitalization, NPJ Biofilms Microbiomes

Xiao, Tang, Zheng, Liu, Li et al., Evidence for gastrointestinal infection of sars-cov-2, Gastroenterology

Yagisawa, Foster, Hanaki, Omura, Global trends in clinical studies of ivermectin in covid-19, Jpn J Antibiot

Zein, Sulistiyana, Raffaelo, Pranata, Ivermectin and mortality in patients with covid-19: A systematic review, meta-analysis, and meta-regression of randomized controlled trials, Diabetes Metab Syndr

Zuo, Zhang, Lui, Yeoh, Li et al., Alterations in gut microbiota of patients with covid-19 during time of hospitalization, Gastroenterology

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

@CovidAnalysis

FAQ

Public domain CC0 1.0